Efficacy of caspofungin against Aspergillus terreus

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 12, 2005, Pages 5133-5135

  Barchiesi, Francesco ^a   Spreghini, Elisabetta ^a   Santinelli, Alfredo ^a   Fothergill, Annette W ^d   Fallani, Stefania ^c   Manso, Esther ^b   Pisa, Eleonora ^a   Giannini, Daniele ^a   Novelli, Andrea ^c   Cassetta, Maria I ^c   Mazzei, Teresita ^c   Rinaldi, Michael G ^d,e   Scalise, Giorgio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d Mays Cancer Center at UT Health San Antonio   (United States)

^e SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; CYCLOPHOSPHAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS TERREUS; BRAIN; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FUNGUS GROWTH; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MOUSE STRAIN; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; DISEASE MODELS, ANIMAL; MICE; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC;

EID: 28844453525     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.12.5133-5135.2005     Document Type: Article

References (13)

1. Arikan, S., M. Lozano-Chiu, V. Paetznick, and J. H. Rex. 2001. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. 45:327-330.
2. Denning, D. 1998. Invasive aspergillosis. Clin. Infect. Dis. 26:781-785.
3. Graybill, J. R., S. Hernandez, R. Bocanegra, and L. K. Najvar. 2004. Antifungal therapy of murine Aspergillus terreus infection. Antimicrob. Agents Chemother. 48:3715-3719.
4. Hajdu, R., R. Thompson, J. G. Sundelof, B. A. Pelak, F. A. Bouffard, J. F. Dropinski, and H. Kropp. 1997. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2339-2344.
5. Iwen, P., M. Rupp, A. Langnas, E. Reed, and S. Hinrichs. 1998. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin. Infect. Dis. 26:1092-1097.
6. Latgé, J.-P. 1999. Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 12:310-350.
7. Maertens, J., I. Raad, G. Petrikkos, M. Boogaerts, D. Selleslag, F. B. Petersen, C. A. Sable, N. A. Kartsonis, A. Ngai, A. Taylor, T. F. Patterson, D. W. Denning, T. J. Walsh, and the Caspofungin Salvage Aspergillosis Study Group. 2004. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 39:1563-1571.
8. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Approved standard M38-A. National Committee for Clinical Laboratory, Wayne, Pa.
9. Schwartz, M., W. Kline, and B. Matuszewski. 1997. Determination of a cyclic hexapeptide (L-743 872), a novel pneumocandin antifungal agent in human plasma and urine, by high-performance liquid chromatography with fluorescence detection. Analytica Chimica Acta 352:299-307.
10. Steinbach, W. J., D. K. Benjamin, Jr., D. P. Kontoyiannis, J. R. Perfect, I. Lutsar, K. A. Marr, M. S. Lionakis, H. A. Torres, H. Jafri, and T. J. Walsh. 2004. Infections due to Aspergillus terreus: multicenter retrospective analysis of 80 cases. Clin. Infect. Dis. 39:192-199.
11. Steinbach, W. J., J. R. Perfect, W. A. Schell, T. J. Walsh, and D. K. Benjamin, Jr. 2004. In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob. Agents Chemother. 48:3217-3225.
12. Sutton, D. A., S. E. Sanche, S. G. Revankar, A. W. Fothergill, and M. G. Rinaldi. 1999. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J. Clin. Microbiol. 37:2343-2345.
13. Walsh, T. J., V. Petraitis, R. Petraitiene, A. Field-Ridley, D. Sutton, M. Ghannoum, T. Sein, R. Schaufele, J. Peter, J. Bacher, H. Casler, D. Armstrong, A. Espinel-Ingroff, M. G. Rinaldi, and C. A. Lyman. 2003. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J. Infect. Dis. 188:305-319.